Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

A novel estetrol-containing combined oral contraceptive: European expert panel review

Lookup NU author(s): Dr Dina Mansour

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. Purpose: Despite considerable advances in recently developed combined oral contraceptives (COCs), resulting in lower rates of adverse events while maintaining contraceptive efficacy, there is interest in further innovation. Materials and Methods: Estetrol (E4), a native oestrogen, and progestin drospirenone (DRSP) were combined in a new COC. A European expert panel reviewed the pharmacology, efficacy, and safety and tolerability of this combination. Their findings are presented as a narrative review. Results: E4 15 mg/DRSP 3 mg in a 24/4 regimen provided effective contraception with good cycle control, characterised by a predictable regular bleeding pattern and minimal unscheduled bleeding, together with a good safety profile. The combination was associated with high user satisfaction, well-being, and minimal changes in body weight. The effects on endocrine and metabolic parameters were limited, and the combination was found to have a limited impact on liver function and lipid and carbohydrate metabolism. Moreover, its effect on several haemostatic parameters was lower than that of comparators containing ethinyl oestradiol (EE) 20 µg/DRSP 3 mg and EE 30 µg/levonorgestrel 150 µg. Conclusion: E4 15 mg/DRSP 3 mg provides safe and effective contraception, with high user satisfaction and predictable bleeding. Further research will evaluate the long-term safety of the COC.

Publication metadata

Author(s): Gemzell-Danielsson K, Cagnacci A, Chabbert-Buffet N, Douxfils J, Foidart J-M, Kubba A, Lete Lasa LI, Mansour D, Neulen J, Neves J, Palma F, Romer T, Spaczynski R, Toth V

Publication type: Review

Publication status: Published

Journal: European Journal of Contraception and Reproductive Health Care

Year: 2022

Volume: 27

Issue: 5

Pages: 373-383

Online publication date: 21/07/2022

Acceptance date: 21/06/2022

ISSN (print): 1362-5187

ISSN (electronic): 1473-0782

Publisher: Taylor and Francis Ltd.

URL: https://doi.org/10.1080/13625187.2022.2093850

DOI: 10.1080/13625187.2022.2093850

Share